Compare Novartis AG (NVS) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Global X SuperDividend ETF — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Global X SuperDividend ETF trades at $24.87. The key difference: Novartis AG pays a 3.17% dividend while Global X SuperDividend ETF pays none, and Novartis AG is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals.
| NVS | SDIV | |
|---|---|---|
Market Cap | $290.25B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $168.62 | $26.34 |
52-Week Low | $113.50 | $22.90 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
